Pichamon Promsena
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Pichamon Promsena has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Suthinee Rutnin
Division of Dermatology, Department of Medicine, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand
2 shared publications - Wimolsiri Iamsumang
Division of Dermatology, Department of Medicine, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand
2 shared publications Annarita Antelmi
Department of Occupational and Environmental Dermatology, Faculty of Medicine Lund University, Skåne University Hospital Malmö Sweden
1 shared publication- Cecilia Svedman
Department of Occupational and Environmental Dermatology Skåne University Hospital, Lund University Malmö Sweden
1 shared publication Jakob Dahlin
Department of Occupational and Environmental Dermatology, Faculty of Medicine Lund University, Skåne University Hospital Malmö Sweden
1 shared publicationKevin Bertilsson
Department of Occupational and Environmental Dermatology, Faculty of Medicine Lund University, Skåne University Hospital Malmö Sweden
1 shared publication
Latest Publications
- Open Access
- 1 November 2025
- Published by Taylor & Francis in Clinical, Cosmetic and Investigational Dermatology
- Vol. ume 18, 3203-3211
Clinicopathological Characteristics of Lichenoid Drug Eruption: A 17-Year Retrospective Study
Purpose: This study aims to characterize the etiology, clinicopathological features, laboratory findings, management strategies, and clinical outcomes of patients diagnosed with lichenoid drug eruption (LDE). Patients and Methods: A retrospective review was conducted on all biopsy-confirmed LDE cases from January 2008 to October 2024. Data collection included clinical characteristics, causative medications, histopathological as well as laboratory findings, and therapeutic responses. Results: Of the 34 patients, half were male, with a mean age of 65.1 years. LDE most commonly presented as erythematous to violaceous lesions, appearing as patches and plaques, predominantly on the extremities. Histopathology showed lichenoid infiltrates in all cases, with focal infiltration in 58.8%. Parakeratosis was present in 17.7%. Necrotic keratinocytes were found in the basal layer in 82.4% and in the spinous layer in 38.2% of cases. Eosinophilic infiltration was observed in approximately one-third of patients. The most common offending agents were calcium channel blockers (CCBs) (42.5%), followed by statins (25.8%). The median latency period from drug initiation to symptom onset was 10.1 months (interquartile range [IQR] 3.0– 45.5). Discontinuation of the causative agent combined with topical corticosteroid therapy resulted in clinical improvement in 73.5% of patients, with a median resolution time of 56 days (IQR 28.0– 77.0). Conclusion: Antihypertensive drugs, especially CCBs, were the most frequently implicated triggers of LDE. In addition to lichenoid dermatitis, eosinophilic infiltration served as a key histopathological hallmark of this condition. Timely identification and withdrawal of the causative medication, combined with appropriate treatment, are essential for achieving favorable clinical outcomes.
- 1 November 2025
- Published by Taylor & Francis in Clinical, Cosmetic and Investigational Dermatology
- Vol. ume 18, 3203-3211
Open AccessClinicopathological Characteristics of Lichenoid Drug Eruption: A 17-Year Retrospective Study
Purpose: This study aims to characterize the etiology, clinicopathological features, laboratory findings, management strategies, and clinical outcomes of patients diagnosed with lichenoid drug eruption (LDE). Patients and Methods: A retrospective review was conducted on all biopsy-confirmed LDE cases from January 2008 to October 2024. Data collection included clinical characteristics, causative medications, histopathological as well as laboratory findings, and therapeutic responses. Results: Of the 34 patients, half were male, with a mean age of 65.1 years. LDE most commonly presented as erythematous to violaceous lesions, appearing as patches and plaques, predominantly on the extremities. Histopathology showed lichenoid infiltrates in all cases, with focal infiltration in 58.8%. Parakeratosis was present in 17.7%. Necrotic keratinocytes were found in the basal layer in 82.4% and in the spinous layer in 38.2% of cases. Eosinophilic infiltration was observed in approximately one-third of patients. The most common offending agents were calcium channel blockers (CCBs) (42.5%), followed by statins (25.8%). The median latency period from drug initiation to symptom onset was 10.1 months (interquartile range [IQR] 3.0– 45.5). Discontinuation of the causative agent combined with topical corticosteroid therapy resulted in clinical improvement in 73.5% of patients, with a median resolution time of 56 days (IQR 28.0– 77.0). Conclusion: Antihypertensive drugs, especially CCBs, were the most frequently implicated triggers of LDE. In addition to lichenoid dermatitis, eosinophilic infiltration served as a key histopathological hallmark of this condition. Timely identification and withdrawal of the causative medication, combined with appropriate treatment, are essential for achieving favorable clinical outcomes.
- Open Access
- 19 May 2025
- Published by Wiley in Contact Dermatitis
- Vol. 93 (3) , 257-259
p‐Phenylenediamine‐Free Hair Dye?—Misleading Labelling Causing Allergic Contact Dermatitis
We report three cases of contact allergy to a mislabelled hair dye product. A hair dye product labelled as p‐phenylenediamine‐free has been found to contain p‐phenylenediamine by a chemical analysis at the level above the limits allowed in the product.
- 19 May 2025
- Published by Wiley in Contact Dermatitis
- Vol. 93 (3) , 257-259
Open Accessp‐Phenylenediamine‐Free Hair Dye?—Misleading Labelling Causing Allergic Contact Dermatitis
We report three cases of contact allergy to a mislabelled hair dye product. A hair dye product labelled as p‐phenylenediamine‐free has been found to contain p‐phenylenediamine by a chemical analysis at the level above the limits allowed in the product.
- Open Access
- 1 September 2023
- Published by Taylor & Francis in Clinical, Cosmetic and Investigational Dermatology
- Vol. ume 16, 2497-2502
Two Case Reports of Elastolytic Giant Cell Granuloma on the Palms
Elastolytic giant cell granuloma (EGCG) is a rare granulomatous reaction hypothesized to occur because of the altered antigenicity of elastic fibers, resulting in cellular immunological reactions. The hallmarks of EGCG include elastolysis, elastophagocytosis, and multinucleated giant cell infiltrations. EGCG was first described as an actinic granuloma or annular elastolytic giant cell granuloma that classically presents as centrifugally expanding annular plaques on sun-exposed areas. It was recently named EGCG due to reports of non-annular lesions in various sun-protected areas. Hand involvement has been described but is almost exclusively confined to the dorsal and lateral aspects of the hands. Herein, we report two cases of EGCG on the palms, an unusual site of presentation, that were successfully treated with topical, high-potency corticosteroids. EGCG should be included in the differential diagnosis in cases of annular skin lesions located on the marginal area of the palms.
- 1 September 2023
- Published by Taylor & Francis in Clinical, Cosmetic and Investigational Dermatology
- Vol. ume 16, 2497-2502
Open AccessTwo Case Reports of Elastolytic Giant Cell Granuloma on the Palms
Elastolytic giant cell granuloma (EGCG) is a rare granulomatous reaction hypothesized to occur because of the altered antigenicity of elastic fibers, resulting in cellular immunological reactions. The hallmarks of EGCG include elastolysis, elastophagocytosis, and multinucleated giant cell infiltrations. EGCG was first described as an actinic granuloma or annular elastolytic giant cell granuloma that classically presents as centrifugally expanding annular plaques on sun-exposed areas. It was recently named EGCG due to reports of non-annular lesions in various sun-protected areas. Hand involvement has been described but is almost exclusively confined to the dorsal and lateral aspects of the hands. Herein, we report two cases of EGCG on the palms, an unusual site of presentation, that were successfully treated with topical, high-potency corticosteroids. EGCG should be included in the differential diagnosis in cases of annular skin lesions located on the marginal area of the palms.